ARTICLE | Clinical News

Orexigen gains on Contrave data

July 30, 2010 11:50 PM UTC

Orexigen Therapeutics Inc. (NASDAQ:OREX) gained $0.45 to $5.20 on Friday after additional data from the Phase III COR-I trial of Contrave were published in the Lancet, including a sensitivity analysis of all patients who completed the full 56 weeks of treatment. The analysis showed that 17% of patients in the high-dose Contrave group and 14% of those in the low-dose Contrave group achieved at least 15% body weight loss, respectively, vs. 3% of placebo patients. ...